• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Blog » Optimal Abilify Dose for Depression (MDD Augmentation with Aripiprazole)

The Carlat Psychiatry Blog
The Carlat Psychiatry Blog RSS FeedRSS

General Psychiatry

Optimal Abilify Dose for Depression (MDD Augmentation with Aripiprazole)

August 13, 2024
Richard Moldawsky, MD and Greg Malzberg, MD
Abilify_Video_thumb.png


In this video, we explore the optimal dose of aripiprazole for depression and how it can be used effectively in antidepressant augmentation. Aripiprazole is one of the most well-studied atypical antipsychotics for depression, particularly in cases of treatment-resistant depression where standard SSRIs and SNRIs have failed to deliver results. But finding the best dose of aripiprazole is critical to balancing its benefits with potential side effects like akathisia and sedation.

This video breaks down the findings from a meta-analysis of randomized controlled trials, examining how aripiprazole dosage impacts patient outcomes in clinical depression treatment. We discuss how doses between 2-5 mg/day can lead to significant improvements on the Montgomery-Åsberg Depression Rating Scale, and why higher doses may not provide additional benefits in most patients. You’ll also learn how aripiprazole augmentation can improve the effectiveness of SSRI and SNRI therapies, helping patients who struggle with treatment-resistant depression.

If you're interested in understanding the clinical benefits of aripiprazole, this video provides clear guidance on its use in mental health treatment. We delve into how this atypical antipsychotic works as an augmenting agent for depression medications, improving the efficacy of existing treatments while minimizing adverse effects. For psychiatric care providers and patients alike, this is essential information on how to best utilize aripiprazole for depression. Whether you're managing treatment-resistant depression or seeking to optimize your mental health treatment, understanding the aripiprazole dosage guide is key to achieving better outcomes.

This video helps clarify the best practices for using aripiprazole in clinical depression treatment, while also explaining how to avoid common aripiprazole side effects and ensure safe, effective treatment. With expert insights and the latest research, we explore the clinical benefits of aripiprazole and offer practical recommendations on aripiprazole dosing for treatment-resistant depression. Join us for an in-depth discussion that could change the way you approach depression care.

Related:

  • How to Treat Depression in Older Adults
  • What Is Neuroscience-Based Nomenclature?
  • Aripiprazole Augmentation May Improve Remission Rates in MDD
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.